Physician profile
Thomas Crenshaw
NPI 1154356426
$4,552.45
in general payments reported to CMS, 2019-2025
25 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $278 · 2021: $268 · 2022: $539 · 2023: $495 · 2024: $235 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,200 · Food and Beverage: $630 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,200.00 |
| Food and Beverage | $630.38 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,215.35 | 2022-2025 | |
| Abbvie INC. | $515.84 | 2019-2023 | Ubrelvy, Lo Loestrin Fe, Orilissa |
| Amgen INC. | $328.54 | 2019-2020 | |
| Daiichi Sankyo INC. | $321.47 | 2019-2024 | Injectafer |
| Channel Medsystems, INC. | $220.47 | 2022-2023 | |
| Pfizer INC. | $157.84 | 2019-2023 | |
| Astellas Pharma US INC | $138.38 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $86.23 | 2019-2023 | Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $82.68 | 2020-2024 | |
| Therapeuticsmd, INC. | $75.83 | 2019-2021 | |
| Novo Nordisk INC | $60.91 | 2022-2023 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $46.13 | 2024 | Exparel |
| Mylan Pharmaceuticals INC. | $42.09 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $40.69 | 2021-2022 | |
| Boston Scientific Corporation | $28.31 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.24 | 2023 | Truclear |
| Organon LLC | $26.74 | 2024 | |
| Minerva Surgical, INC | $25.99 | 2021-2022 | |
| Lupin INC. | $23.50 | 2019-2021 | |
| Biogen, INC. | $23.10 | 2024 | |
| Shield Therapeutics INC | $15.13 | 2024 | |
| Coopersurgical, INC. | $12.80 | 2020 | |
| Evofem Biosciences, INC. | $12.65 | 2021 | |
| Avion Pharmaceuticals | $12.20 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.